Providers

A group of researchers has compiled the latest advancements in preventing and treating graft-vs-host disease (GVHD).

Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.

An analysis of nationwide data over 2 decades identified demographic-specific trends in liver cancer incidence and mortality in the US.

A single-center, retrospective study demonstrated the major success of immunosuppressive therapies in contributing to complete remission in patients with acquired hemophilia A.

Venetoclax and azacitidine was found safe, but further randomized trials are needed to determine the full extent of the combination’s efficacy in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Investigators used a predictive model factoring in lymphopenia, elevated SIL2R level, extranodal involvement, and a positive hepatitis panel to determine risk for febrile neutropenia among patients with diffuse large B-cell lymphoma (DLBCL).

The critical issue of mental health in the workplace was discussed by experts in the field at the recent Midwest Business Group on Health (MBGH) Mental Health Forum, shedding light on the growing concern surrounding alcohol use disorder and the pressing need for innovative therapies.

While dietary interventions do not significantly change the body composition of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA), they can reduce the risk of cardiovascular disease (CVD).

A comparative analysis on skin cancer management guidelines in the US highlights the necessity of further research in this subject.

Patients with diabetes whose providers received advice from remote, virtual interdisciplinary rounds had a greater 1-year reduction in hemoglobin A1c than comparable patients.

A review of research confirms that adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) face psychological burdens but the exact burden is poorly understood.

The group showed that their 14-day model using an easily measurable calculation was able to predict long-term mortality as well as the traditional model using responses from 2 weeks later.

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population.

Knowledge gaps persist in awareness of and education on the use of chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, especially multiple myeloma and lymphoma.

A recent study found that tumor-stroma proportion was a reliable marker of chemoresistance, progression-free survival, and overall survival in high-grade serous ovarian cancer.

Starting summer 2024, individuals across the US will be able to purchase a continuous glucose monitor (CGM) without needing a prescription.

Despite its impact on patient quality of life, hidradenitis suppurativa (HS) remains underdiagnosed and undertreated; authors outline what's being discovered within the treatment landscape.

Identifying and addressing unmet social needs without attention to other contributors to health inequities—such as medical mistrust—is unlikely to yield desired outcomes.

However, prevalence was found to plateau over time, suggesting neuropathic pain may be isolated or intermittent events in some patients with type 1 diabetes.

The National Comprehensive Cancer Network (NCCN) recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.

Modeling estimates indicate that annual breast cancer screening starting at age 40 years provides the greatest benefit to women and reduces risk per examination.

No generalized statements regarding nurse practitioners’ low-value care ordering practices can be made due to limited evidence, indicating a need for further research.

Young investigators spoke to emerging metabolic and cognitive research in multiple sclerosis (MS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.